Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Matthew Wolpin, M.D.

Co-Author

This page shows the publications co-authored by Brian Wolpin and Thomas Clancy.
Connection Strength

1.899
  1. FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma. Cancer Discov. 2021 Oct; 11(10):2488-2505.
    View in: PubMed
    Score: 0.240
  2. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Clin Cancer Res. 2021 02 15; 27(4):1069-1081.
    View in: PubMed
    Score: 0.233
  3. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Genet Med. 2019 01; 21(1):213-223.
    View in: PubMed
    Score: 0.197
  4. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.196
  5. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.
    View in: PubMed
    Score: 0.193
  6. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.
    View in: PubMed
    Score: 0.187
  7. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma. J Clin Oncol. 2017 Feb 10; 35(5):485-489.
    View in: PubMed
    Score: 0.178
  8. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol. 2015 Jan 01; 33(1):29-35.
    View in: PubMed
    Score: 0.153
  9. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021 Aug; 11(8):2014-2031.
    View in: PubMed
    Score: 0.059
  10. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection. Gastroenterology. 2021 03; 160(4):1373-1383.e6.
    View in: PubMed
    Score: 0.058
  11. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2020 08; 29(8):1586-1595.
    View in: PubMed
    Score: 0.056
  12. Neoadjuvant Therapy is Associated with Improved Survival in Borderline-Resectable Pancreatic Cancer. Ann Surg Oncol. 2020 Apr; 27(4):1191-1200.
    View in: PubMed
    Score: 0.054
  13. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017 Sep 01; 28(9):2067-2076.
    View in: PubMed
    Score: 0.047
  14. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Ann Oncol. 2017 09 01; 28(9):2316.
    View in: PubMed
    Score: 0.047
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.